Drugs / Metacavir
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03180333 | Mar → Aug 2012 | chronic hepatitis B virus infection | Guangzhou Yipinhong Pharmaceutical CO.,LTD | Completed | No outcome recorded |
| Phase 1 | NCT03173599 | Dec 2010 → Apr 2011 | chronic hepatitis B virus infection | Guangzhou Yipinhong Pharmaceutical CO.,LTD | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02965859 | Dec 2012 → Dec 2018 | chronic hepatitis B virus infection | Guangzhou Yipinhong Pharmaceutical CO.,LTD | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metacavir | “Multiple dosing tolerance test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 7 days;” NCT03180333 ↗2“The Safety and Tolerability of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers” NCT03173599 ↗ |
| Known as | Metacavir Enteric-coated Capsules | “The Safety and Tolerability of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers” NCT03173599 ↗ |
| Modality | Small molecule | — CHEMBL243716 ↗ |
| Route | Oral | “to orally take a single dose of Metacavir enteric-coated capsule or placebo on the condition of fasting” NCT03173599 ↗ |